Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Chase Doyle

Authored Items
ASCO Updates Its Oncology Medical Home Payment Model, Putting Patient Needs Up Front
Chase Doyle
TOP - July 2020, Vol 13, No 4 in Value-Based Care
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
TOP - March 2020, Vol 13, No 2 in Value-Based Care
Tazemetostat Demonstrates Antitumor Activity in Relapsed/Refractory Follicular Lymphoma
Chase Doyle
TOP - March 2020, Vol 13, No 2
Delivering High-Value Personalized Interventions
Chase Doyle
Web Exclusives in Clinical Pathways
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
Chase Doyle
Web Exclusives in Clinical Trials
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Chase Doyle
TOP - November 2019, Vol 12, No 4 in Clinical Pathways
Oral Parity Laws Could Reduce Disparities in Cancer Care
Chase Doyle
TOP - November 2019, Vol 12, No 4 in Disparities in Oncology
Oral Parity Laws Could Reduce Disparities in Cancer Care
Chase Doyle
Web Exclusives in Disparities in Oncology
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Chase Doyle
Web Exclusives in Clinical Pathways
Financial Toxicity High for Low-Income Patients in Early-Phase Clinical Trials
Chase Doyle
Web Exclusives in Financial Toxicity
Oncology Reimbursement Reform: Changes on the Horizon
Chase Doyle
TOP - August 2019, Vol 12, No 3 in ASCO
CAR T-Cell Therapy Targeting Solid Tumors
Chase Doyle
TOP - August 2019, Vol 12, No 3 in Immunotherapy
FDA Perspective: Reducing Cost, Increasing Access to Cancer Care
Chase Doyle
TOP - February 2019, Vol 12, No 1 in Health Policy
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TOP - November 2018, Vol 11, No 3 in HOPA
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
Web Exclusives in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
Web Exclusives in Immunotherapy
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
TOP - November 2017, Vol 10, No 4 in Multiple Myeloma
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Prescription Drug Use High Among Survivors of Childhood Cancers
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Survivorship
Shared Antigens Yield Promising Targets for Cancer Prevention
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Immunotherapy
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Chemotherapy Treatment Considerations in Special Patient Populations
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Conference Correspondent, HOPA
Rapid Adoption of Novel Oncology Drugs Improves Overall Survival
Chase Doyle
TOP - August 2017, Vol 10, No 3 in Survivorship
Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Lung Cancer
Plinabulin Improves Survival in Non–Small-Cell Lung Cancer
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Lung Cancer
Nivolumab versus Cabozantinib: Second-Line Therapy for Metastatic Renal-Cell Carcinoma Still Unresolved
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA
Provider Status Initiative Takes Center Stage at HOPA
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA
Right-to-Try Laws Challenge Pharmacy Code of Ethics
Chase Doyle
TOP - May 2017, Vol 10, No 2 in HOPA
Mechanisms of Response and Resistance to Immunotherapy
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Immunotherapy
Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab
Chase Doyle
TOP - May 2017, Vol 10, No 2 in Immunotherapy
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Chase Doyle
Web Exclusives in Conference Correspondent, In the News
Drug–Drug Interactions Linked to Inferior Survival in Older Patients with Aggressive Lymphoma
Chase Doyle
TOP - February 2017, Vol 10, No 1 in Palliative Care
Managing Immune-Related Toxicities
Chase Doyle
TOP - November 2016, Vol 9, No 4 in Supportive Care
Survivorship Care: A Patient Advocate’s Prescription
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
Decision Aids: Facilitating Communication with Cancer Survivors
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities
Chase Doyle
TOP - May 2016, Vol 9, No 2 in Survivorship
Immunotherapy Will Alter the NSCLC Treatment Landscape
Chase Doyle
TOP November 2015 Vol 8 No 4 in Immunotherapy
Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Chase Doyle
TOP November 2015 Vol 8 No 4 in Genitourinary Cancers
Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Chase Doyle
Online First in Online First, Genitourinary Cancers
Stereotactic Body Radiation Therapy Shows Acceptable Urinary and Sexual Toxicity
Chase Doyle
TOP - August 2015, Vol 8, No 3 in Genitourinary Cancers
Higher Costs for Sunitinib versus Pazopanib in Patients with Renal-Cell Carcinoma
Chase Doyle
TOP - August 2015, Vol 8, No 3 in Genitourinary Cancers
Colorectal Cancer Survivors Frequently Report Bowel Dysfunction
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Supportive Care
Biosimilar Effective for Chemotherapy-Induced Anemia in Patients with Colorectal Cancer
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Best Practices
Investigational Drug for Cachexia Appears to Improve Survival
Chase Doyle
TOP - May 2015, Vol 8, No 2 in Colorectal Cancer
Symptom Management Drives Value in Oncology
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Supportive Care
Biosimilars: Ambiguity of FDA Terminology and Benefits of a Multidisciplinary Review Team
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Best Practices
Addressing Patient Safety for Oral Chemotherapy
Chase Doyle
TOP - February 2015, Vol 8, No 1 in Best Practices
Last modified: December 11, 2015